The global impact and cost-effectiveness of a melioidosis vaccine

Every year, 90,000 people may die from melioidosis. Vaccine candidates have not proceeded past animal studies, partly due to uncertainty around the potential market size. This study aims to estimate the potential impact, cost-effectiveness and market size for melioidosis vaccines. Age-structured decision tree models with country-specific inputs were used to estimate net costs and health benefits of vaccination, with health measured in...